Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Sangamo BioSciences said data from its Phase Ib trial for its investigational drug demonstrate statistically significant improvements in quantitative measurements of neurological health in subjects with diabetic neuropathy, suggesting an alteration of disease progression.
Subscribe to our email newsletter
Additional data were presented suggesting that a single treatment with SB-509 may increase the mobilization of stem cells into a subject’s blood. These circulating stem cells may have implications for the nerve regeneration and nerve and blood vessel growth that have been reported from SB-509 treatment.
In this study subjects received a single treatment in both legs of either placebo (10 subjects) or SB-509 (10 subjects who received 60mg total dose or 30mg per leg). All of the subjects completed six-month follow-up testing. Clinicians observed statistically significant clinical improvements in quantitative sensory testing (QST) which quantifies perception of vibration.
Clinicians also observed a trend for improvement in SB-509 treated patients in a composite measure of nerve health, the modified total neuropathy score or TNS.
Edward Lanphier, president and CEO of Sangamo BioSciences, said: “We continue to be very pleased and impressed by the disease-altering improvements that we have observed in several measurements of nerve health in subjects with mild to moderate diabetic neuropathy treated with SB-509.”